Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis
JCO Precision Oncology · 2026-07 · 10 (7)
DOI: 10.1200/po-25-01110 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Yilin Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Curta Inc, Seattle, WA. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Cost-Benefit Analysis, Endometrial Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE We assessed the cost-effectiveness of Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) testing versus no molecular testing to guide initial treatment in stage III/IV primary advanced or recurrent endometrial cancer (pA/rEC) from payer and societal perspectives. METHODS A decision tree for molecular classification followed by a partitioned survival model estimated lifetime costs and outcomes for ProMisE versus no testing. Patients in the no testing arm received carboplatin + paclitaxel (CP), dostarlimab + CP, pembrolizumab + CP, or hormonal therapy (everolimus + letrozole). Patients in the ProMisE arm received the same treatments or bevacizumab + CP. Survival functions were derived from trial results. EQ-5D-5L utility values were from the RUBY trial (ClinicalTrials.gov identifier: NCT03981796 ). Costs were sourced from US databases and literature. The base case presented a US third-party payer perspective. A scenario analysis presented a modified societal perspective. Outcomes were total life-years (LYs), total quality-adjusted LYs (QALYs), total costs, and incremental cost-effectiveness ratio (ICER) of ProMisE versus no testing. RESULTS From a payer perspective, total LYs and total QALYs were 5.36 and 4.08 with ProMisE versus 3.83 and 2.89 with no testing, respectively. Total costs were $233,989 US dollars (USD) with ProMisE versus $155,305 USD with no testing. Incremental LYs and QALYs were 1.53 and 1.19 greater with ProMisE; incremental costs over a lifetime were $78,684 USD greater with ProMisE. Assuming a threshold of $150,000 USD per QALY gained, ProMisE was cost effective with an ICER of $66,321 USD per QALY gained. From a societal perspective, lifetime costs were lower (–$22,973 USD) and QALYs greater with ProMisE versus no testing. CONCLUSION ProMisE testing is cost effective compared with no testing. Given the heterogeneity of molecular subtypes in stage III/IV pA/rEC, molecular testing enables personalized treatment that is both clinically meaningful and of high value from payer and societal perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Curta Inc, Seattle, WA.
- GSK, Collegeville, PA.
- University of Washington, Seattle, WA.
ORCID-Profile: Yilin Chen, Solomon J Lubinga, Scott Ramsey, Jean Hurteau, Josh J Carlson
Zitieren
APA
Chen, Y., Lubinga, S. J., Ramsey, S., Hurteau, J., Reynolds, J., & Carlson, J. J. (2026). Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-25-01110
Vancouver
Chen Y, Lubinga SJ, Ramsey S, Hurteau J, Reynolds J, Carlson JJ. Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-25-01110
BibTeX
@article{Chen2026,
author = {Chen, Yilin and Lubinga, Solomon J and Ramsey, Scott and Hurteau, Jean and Reynolds, Jade and Carlson, Josh J},
title = {Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {7},
doi = {10.1200/po-25-01110}
}
EUVIMED